Deutsche Beteiligungs AG

  • WKN: A1TNUT
  • ISIN: DE000A1TNUT7
  • Land: Germany

Nachricht vom 23.01.2012 | 16:44

Deutsche Beteiligungs AG: Dividend of 0.80 Euros per share recommended/Consolidated loss of 16.6 million Euros due to unrealised negative valuation movements


Deutsche Beteiligungs AG  / Key word(s): Dividend/Final Results

23.01.2012 16:44

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.


Announcement consistent with § 15 WpHG Deutsche Beteiligungs AG, WKN 550 810/ ISN DE0005508105 Supervisory Board and Board of Management recommend dividend of 0.80 euros per share Surplus dividend following strong realisations / Negative net income of 16.6 million euros At the upcoming Annual Meeting of Deutsche Beteiligungs AG, the Supervisory Board and the Board of Management will recommend paying a dividend of 0.40 euros per share in addition to a surplus dividend of 0.40 euros per share, or a total of 0.80 euros per share for the 2010/2011 financial year (1 November to 31 October). A resolution to that effect was passed today. This continues the dividend policy Deutsche Beteiligungs AG has been pursuing in recent years: a base dividend that is geared to net asset value per share and current money market rates is to be increased by a surplus dividend in years recording successful realisations from the portfolio. For the preceding 2009/2010 financial year, a total of 1.40 euros per share (a base dividend of 0.40 euros and a surplus dividend of 1.00 euro) was paid in March 2011. The Supervisory Board of Deutsche Beteiligungs today also approved the 2010/2011 consolidated financial statements and adopted the 2010/2011 separate financial statements of Deutsche Beteiligungs AG. For 2010/2011, Deutsche Beteiligungs AG posted a consolidated loss of 16.6 million euros. Net asset value therefore fell to 17.47 euros per share. The consolidated loss was substantially due to unrealised negative valuation movements. A prime factor was the price loss of a quoted investment in the portfolio, Homag Group AG. This investment is valued at its stock market quotation on the reporting date. The price of Homag shares dropped from 15.48 euros to 8.48 euros over financial year 2010/2011; this equates to a negative valuation effect of 18.5 million euros on income. Deutsche Beteiligungs AG also uses parameters that derive from the stock market for the valuation of its unquoted investments. The sharp drop in stock market levels beginning in August 2011 therefore also had a negative impact on the valuation of the other companies in the portfolio. The Company's liquidity was not compromised by the consolidated loss. At the reporting date on 31 October, Deutsche Beteiligungs AG had cash and securities totalling 155.6 million euros, an increase of 15 million euros over the preceding year. The rise stems, among other things, from proceeds from the realisation of Heim & Haus GmbH and the (partial) disinvestment of Preh GmbH in May and June. The Company will issue its consolidated financial statements on 26 January 2012. The Board of Management Frankfurt am Main, 23 January 2012 23.01.2012 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de
Language: English Company: Deutsche Beteiligungs AG Börsenstrasse 1 60313 Frankfurt am Main Germany Phone: +49 (0)69 957 87-01 Fax: +49 (0)69 957 87-199 E-mail: welcome@deutsche-beteiligung.de Internet: www.deutsche-beteiligung.de ISIN: DE0005508105 WKN: 550810 Indices: SDAX Listed: Regulierter Markt in Düsseldorf, Frankfurt (Prime Standard); Freiverkehr in Berlin, Hamburg, München, Stuttgart End of Announcement DGAP News-Service

GBC im Fokus

MagForce AG:

Die kommerzielle Behandlung mit der MagForce-Technologie wird nun auch vom Klinikum Vivantes Friedrichshain abgedeckt. Damit kommt diese neue Technologie bereits in vier Kliniken in Deutschland für die kommerzielle Behandlung bösartiger Hirntumore zum Einsatz, was als eine gute Basis für einen Anstieg der Behandlungsumsätze anzusehen ist. Parallel dazu rechnen wir mit der Marktzulassung zur Behandlung von Prostatakrebs in den USA zum Ende des Geschäftsjahres 2017. Wir vergeben das Rating KAUFEN.

News im Fokus

Deutsche Post AG: Informationen zum Aktienrückkauf - 2. Tranche

27. Mai 2016, 17:05

Aktueller Webcast

windeln.de AG

Q1 2016 Earnings Call

24. Mai 2016

Aktuelle Research-Studie

Edel AG

Original-Research: Edel AG (von Montega AG): Kaufen

26. Mai 2016